Boehringer Ingelheim
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.15 | 9 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 3 | ×0.87 | 4 |
| approved | ×1.50 | 3 |
Strategy profile
Based on 15 disclosed transactions, Boehringer Ingelheim concentrates its licensing activity in Immunology, Gastroenterology, and Cardiovascular. Boehringer Ingelheim pays a 1.15x premium over market median, with the strongest premiums in Oncology (1.15x). Their most common deal structure is License, with an average disclosed value of $677M. Most recent activity: 2026.
Premium by therapeutic area
How Boehringer Ingelheim pays relative to peer medians in each TA
Pipeline coverage & gaps
Boehringer Ingelheim has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $46M | $774M |
| Collaboration | 4 | $2M | $470M |
| Option | 3 | $27M | $695M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | SIM0709 | Simcere | inflammatory bowel disease | preclinical | $46M | $1.2B |
| 2026 | SIM0709 | Simcere Pharmaceutical Group | inflammatory bowel disease | preclinical | $47M | $1.2B |
| 2026 | Cardiovascular disease collaboration expansion | Variant Bio | cardiovascular disease | discovery | — | $250M |
| 2026 | AI-driven RNA splicing platform (oncology) | Envisagenics | oncology | discovery | — | $1.0B |
| 2026 | HTL-0048149 (GPR52 agonists) | Nxera Pharma | schizophrenia | preclinical | $28M | $830M |
| 2026 | HTL-0048149 (GPR52 agonists) | Nxera Pharma | schizophrenia | preclinical | $27M | $825M |
| 2026 | undisclosed preclinical inflammatory disease asset | Immunitas Therapeutics | inflammatory disease | preclinical | — | $430M |
| 2026 | Immunitas inflammatory asset | Immunitas | inflammatory / autoimmune disorders | unknown | — | $448M |
| 2026 | small-molecule immune-disease program | Sitryx Therapeutics | autoimmune and inflammatory diseases | preclinical | — | $500M |
| 2026 | SIM0709 | Simcere Pharmaceutical Group | inflammatory bowel disease | preclinical | $46M | $1.2B |
| 2025 | — | Rectify Pharmaceuticals, Inc. | Chronic kidney disease (CKD) | preclinical | — | $448M |
| 2025 | CDR111 (trispecific M-gager T-cell engager, autoimmune) | CDR-Life, Inc. | — | preclinical | — | $570M |
| 2025 | — | Kyowa Kirin | autoimmune | preclinical | — | $717M |
| 2025 | Melanocortin receptor retinal-disease program | Palatin Technologies | diabetic retinopathy | discovery | $2M | $308M |
| 2025 | Melanocortin-receptor retinal-disease program | Palatin Technologies | diabetic retinopathy | preclinical | $2M | $322M |
How this is computed
For each Boehringer Ingelheim deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 13 disclosed deal premiums vs. peer medians. Raw premium 1.147, clamped to [0.7, 1.5].